Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Executes Stock Sales and Conversions

CEO Christopher Gibson reported the sale of Class A Common Stock and conversion of Class B Common Stock into Class A Common Stock, according to a recent SEC Form 4 filing.

Summary

• Christopher Gibson, CEO of Recursion Pharmaceuticals, filed a Form 4 detailing transactions in the company's stock.
• On April 3, 2024, Gibson sold 65,000 shares of Class A Common Stock at prices of $8.84 and converted 25,000 shares of Class B Common Stock into Class A Common Stock.
• On April 4, 2024, Gibson sold 65,000 shares of Class A Common Stock at a price of $9.02 and converted 25,000 shares of Class B Common Stock into Class A Common Stock.
• These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2023.
• Following these transactions, Gibson directly owns 938,524 shares of Class A Common Stock.
• Gibson also indirectly owns shares through the Gibson Family Trust (25,000 Class A Common Stock and 67,875 Class B Common Stock), LAHWRAN-3 LLC (25,000 Class A Common Stock and 486,000 Class B Common Stock), and LAHWRAN-4 LLC (388,000 Class B Common Stock).

Sentiment

Score: 5

Explanation: Neutral. The filing simply reports transactions under a pre-existing trading plan. It doesn't inherently indicate positive or negative sentiment about the company's future.

Negatives

• The CEO's sale of shares could be interpreted negatively by some investors, although it was conducted under a pre-arranged trading plan.

Risks

• Continued stock sales by the CEO could put downward pressure on the stock price.

Industry Context

Insider transactions are routinely monitored by investors as they can provide insights into management's perspective on the company's valuation and future prospects. However, pre-planned sales under Rule 10b5-1 plans are common and may not necessarily reflect a change in management's outlook.

Stakeholder Impact

• Shareholders may react to the CEO's stock sales, although the pre-planned nature of the transactions may mitigate any negative impact.

Key Dates